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for the development of a post transplant cardiac complication. In
patients who suffered a cardiac complication 38% went onto re-
quire intensive supportive care and this was associated with signif-
icant morbidity. Consideration to add medical prophylaxis in pa-
tients with a risk to develop cardiac complications should be
considered in this high risk group.
215
PALIFERMIN REDUCES THE INCIDENCE OF ORAL MUCOSITIS AFTER
ABLATIVE PREPARATIVE REGIMENS IN PATIENTS UNDERGOING AN
UMBILICAL CORD BLOOD TRANSPLANT
Rodriguez, T.E.1, Toor, A.A.1, Smith, S.E.1, Parthasarathy, M.1,
Stiff, P.J.1 1Bone Marrow Transplant Program, Department of Medi-
cine, Loyola University Chicago, Maywood, IL.
Oral mucositis (OM) is a major cause of morbidity after myeloa-
blative stem cell transplants. Palifermin has shown efﬁcacy in the
prevention of myeloablative therapy-induced OM in patients un-
dergoing autotransplants for hematologic malignancies. We ana-
lyzed data from recipients of umbilical cord blood transplantation
(UCBT) who received palifermin as prophylaxis for OM both
before and after an ablative preparative regimen. Methods: We
identiﬁed 26 UCBT patients at our institution who underwent the
procedure from May 2003 to August 2006. The ﬁrst 15 patients did
not receive palifermin while the most recent 11 patients received
palifermin at a mean total dose of 150 g/kg over 2 consecutive
days, starting 2 days before the initiation of the preparative regi-
men and 2 days after infusion of the UCB cells starting on day 0.
Patient Characteristics: The median age for the patients in the
palifermin vs. non-palifermin groups was 50 (33-58) and 43 (23-56)
years. The preparative regimens used for the palifermin group
consisted of total body irradiation and cyclophosphamide (TBI/
Cy) in 9/11 patients, and BCNU, etoposide, cytarabine and mel-
phalan (BEAM) in 2/11 patients, while in the non-palifermin
group, TBI/CY was used in 7/15 patients, BEAM in 5/15 patients,
and 2/15 patients received busulfan and cyclophosphamide. The
median post-thaw nucleated cell dose for the palifermin vs. non-
palifermin groups was 1.4 and 1.7  107/kg. Results: Mucositis
occurred less frequently (2/11 vs. 12/15; P  0.004, Fisher’s exact
test) and appeared to be less severe in the palifermin treated group
who also did not have a higher incidence of severe acute graft vs.
host disease. No difference was observed in neutrophil (19 vs. 16
days for palifermin vs. non-palifermin) and platelet engraftment
(57 and 51 days respectively) between the groups. Days of fevers
were less frequent in the palifermin group compared to the non-
palifermin group ( median of 1 day vs. 4 days respectively). Median
days of total parenteral nutrition (TPN) was 0 in the palifermin
group vs. 13 days in the non-palifermin group. Conclusion: Pali-
fermin reduces the incidence of OM and the need for TPN but
does not appear to increase the incidence of severe acute GVHD in
recipients of UCBT transplants after myeloablative therapy.
Grade of Mucositis and Acute GVHD With or Without Palifermin
in Umbilical Cord Blood Transplant Patients.
Treatment
Group No.
Mucositis
Grade 0
Mucositis
Grade 1-2
Mucositis
Grade 3-4
GVHD
Grade 0-I
GVHD
Grade
II-IV
GVHD
Grade
III-IV
Palifermin 11 9 1 1 10 1 1
Non-
Palifermin 15 3 9 3 3 7 2
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AMD 3100 SUCCESSFULLY MOBILIZES AUTOLOGOUS CD34 CELLS
AFTER FAILURE OF G-CSF MOBILIZATION REGIMENS WITH LOW TOX-
ICITY AND ACCEPTABLE AUTOLOGOUS STEM CELL TRANSPLANT
(ASCT) OUTCOMES
Shaughnessy, P.J.1, Hougham, M.1, Bachier, C.1, LeMaistre, C.F.1
1Texas Transplant Institute, San Antonio, TX.
AMD3100 reversibly inhibits SDF-1alpha/CXCR4 binding and
induces rapid mobilization of CD34 cells into the circulation
which can potentiate stem cell mobilization by G-CSF alone. We
report our institutional experience using AMD3100, as part of a
larger compassionate use protocol, in patients (pts) who failed to
collect 2 million CD34 cells/kg using standard methods of au-
tologous peripheral blood stem cell mobilization (PBSCM).
Twelve pts (male n6, median age 65 years [range 32-73]) with
non Hodgkins lymphoma (n6), multiple myeloma (n4), and
Hodgkins disease (n2) were treated on study. All pts had failed a
median of 1 prior PBSCM (range 1-3) with chemotherapy followed
by G-CSF(n9) or G-CSF alone (n6). Study treatment was
neupogen 10ug/kg daily in the AM and AMD 3100 240ug/kg
beginning day 4 at 2200. Apheresis of a 3 blood volume exchange
began day ﬁve, 10 hours after the ﬁrst AMD 3100 injection and 1
hour after the daily AM neupogen injection. This schedule con-
tinued daily until adequate CD34 cells were collected or the pts
were taken off study. Eleven (92%) pts mobilized adequate
CD34 cells to proceed with high dose chemotherapy and ASCT.
A median of 2.1 million/kg CD34 cells (range 1.1 to 5.5) were
collected in a median of 3 (range 1-4) apheresis days. The maxi-
mum median peripheral blood CD34 cell count prior to study
was 8 cells/ul (range 1-25) but after administration of AMD3100
increased to 22 cells/ul (range 14-160) (p0.03). Six pts reported
mild reversible adverse events (AEs) possibly related to AMD3100,
and no severe AEs were attributed to study drug. Nine pts pro-
ceeded to high dose chemotherapy and ASCT, 2 pts are pending
start of ASCT, and one pt had insufﬁcient CD34 cells for ASCT.
Eight pts are evaluable for engraftment with a median day to ANC
greater than 500/ul of 12 days (range 11 to 15) and platelets greater
than 20 K/ul of 20 days (range 14 to 39). There was no transplant
related mortality at day 100 or unexpected transplant related tox-
icity. Two of 12 pts have died, both from relapsed disease 6 months
post ASCT. A cohort of 60 pts underwent standard PBSCM and
ASCT during the same time period as the study pts and the groups
will be compared for differences in ASCT outcome and supportive
care needs. In conclusion, this single institution case series of pts
demonstrates that AMD3100 can mobilize signiﬁcantly more
CD34 cells in pts who have failed standard PBSCM, with little
toxicity and acceptable ASCT outcomes.
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EVALUATION OF SINGLE-DOSE PALIFERMIN TO REDUCE MUCOSITIS:
ASSESSMENT OF EFFICACY AND SAFETY IN PATIENTS (PTS) WITH
HEMATOLOGIC MALIGNANCIES (HM) RECEIVING AUTOLOGOUS PE-
RIPHERAL BLOOD PROGENITOR CELL (PBPC) TRANSPLANTATION
Shea, T.1, Kewalramani, T.2, Mun, Y.3, Jayne, J.3, Dreiling, L.3
1University of North Carolina, Chapel Hill, NC; 2Memorial Sloan
Kettering Cancer Center, NY, NY; 3Amgen Inc., Thousand Oaks, CA.
Palifermin has been approved for pts with HM undergoing
PBPC transplantation with a regimen of 3 daily doses of 60 g/kg
pre- and post-myeloablative conditioning. The pre-dosing may,
however, be inconvenient for some pts. This study was initially
developed to demonstrate the non-inferiority of 3 collapsed (180
g/kg) pre-dosing schedules in reducing the incidence of severe
oral mucositis (OM) (WHO grade 3 or 4) induced by fractionated
total body irradiation (fTBI) and high dose chemotherapy in pts
with HM undergoing PBPC transplantation. The study was
stopped early due to the decreased utilization of fTBI resulting in
slow accrual. Methods: Pts were 18 to 74 years old with HM, a
Karnofsky performance score70%, and eligible for fTBI (12 Gy)
followed by cyclophosphamide (100 mg/kg) and optional VP-16
(60 mg/kg), with autologous PBPC support. Pts were randomized
(1:1:1:1) to receive the FDA approved palifermin dose and schedule
of 60 g/kg administered once daily for 3 days prior to the start of
fTBI (control, Arm A) versus palifermin 180 g/kg administered
once only on day -1 (Arm B); day -2 (Arm C); or day -3 (Arm D)
prior to the start of fTBI. Pts were stratiﬁed by VP-16 use and the
number of days of fractionated TBI. All pts received palifermin 60
g/kg for 3 days post transplant (days 0, 1, 2). Results: The
incidence of severe OM has been previously reported for the 47
randomized pts (ASH 2006). The incidence of severe OM was 82%
(9/11), 60% (6/10), 31% (4/13), and 75% (9/12) in Arms A, B, C
and D, respectively. Most adverse events (AEs) occurred at fre-
quencies  10% and had a similar incidence across all treatment
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